Clinical Cooperation Unit Molecular Hematology/Oncology, German Cancer Research Center, DKFZ and Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
Leukemia. 2012 Apr;26(4):728-35. doi: 10.1038/leu.2011.283. Epub 2011 Oct 21.
Constitutive tyrosine kinase activation by reciprocal chromosomal translocation is a common pathogenetic mechanism in chronic myeloproliferative disorders. Since centrosomal proteins have been recurrently identified as translocation partners of tyrosine kinases FGFR1, JAK2, PDGFRα and PDGFRβ in these diseases, a role for the centrosome in oncogenic transformation has been hypothesized. In this study, we addressed the functional role of centrosomally targeted tyrosine kinase activity. First, centrosomal localization was not routinely found for all chimeric fusion proteins tested. Second, targeting of tyrosine kinases to the centrosome by creating artificial chimeric fusion kinases with the centrosomal targeting domain of AKAP450 failed to enhance the oncogenic transforming potential in both Ba/F3 and U2OS cells, although phospho-tyrosine-mediated signal transduction pathways were initiated at the centrosome. We conclude that the centrosomal localization of constitutively activated tyrosine kinases does not contribute to disease pathogenesis in chronic myeloproliferative disorders.
通过相互染色体易位导致的组成型酪氨酸激酶激活是慢性骨髓增殖性疾病的一种常见发病机制。由于中心体蛋白已被反复鉴定为 FGFR1、JAK2、PDGFRα 和 PDGFRβ 酪氨酸激酶的易位伙伴,因此假设中心体在致癌转化中起作用。在这项研究中,我们研究了靶向中心体的酪氨酸激酶活性的功能作用。首先,并非所有测试的嵌合融合蛋白都常规发现中心体定位。其次,通过用 AKAP450 的中心体靶向结构域创建人工嵌合融合激酶将酪氨酸激酶靶向到中心体,虽然磷酸酪氨酸介导的信号转导途径在中心体处起始,但未能增强 Ba/F3 和 U2OS 细胞的致癌转化潜力。我们得出结论,组成型激活的酪氨酸激酶的中心体定位不会导致慢性骨髓增殖性疾病的发病机制。